Genetic and potential antigenic evolution of influenza A(H1N1)pdm09 viruses circulating

in Kenya during 2009-2018 influenza seasons

- 3 D. Collins Owuor^{1*}, Zaydah R. de Laurent¹, Bryan O. Nyawanda², Gideon O. Emukule³, 4 Rebecca Kondor⁴, John R. Barnes⁴, D. James Nokes^{1,5}, Charles N. Agoti^{1,6} and Sandra S.
- 5 Chaves $3,4$
-

Affiliations

- *1. Epidemiology and Demography Department, Kenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme, Kilifi, Kenya.*
- *2. Kenya Medical Research Institute, Kisumu, Kenya.*
- *3. Influenza Division, Centers for Disease Control and Prevention, Nairobi, Kenya.*
- *4. Influenza Division, National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.*
- *5. School of Life Sciences and Zeeman Institute for Systems Biology and Infectious*
- *Disease Epidemiology Research (SBIDER), University of Warwick, Coventry, UK.*
- *6. School of Public Health and Human Sciences, Pwani University, Kilifi, Kenya.*
-

*** Corresponding author.** Dr. D. Collins Owuor (collinsdowuor@gmail.com).

Keywords: Influenza; next-generation sequencing; hemagglutinin; antigenic evolution; 21 genetic groups.

-
-
-

25 **Abstract**

26 **Background.** Influenza viruses undergo rapid evolutionary changes, which requires 27 continuous surveillance to monitor for genetic and potential antigenic changes in circulating 28 viruses that can guide control and prevention decision making.

29

30 **Methods.** We sequenced and phylogenetically analyzed A(H1N1)pdm09 virus genome 31 sequences obtained from specimens collected from hospitalized patients of all ages with or 32 without pneumonia between 2009 and 2018 from seven sentinel surveillance sites across 33 Kenya. We compared these sequences with recommended vaccine strains during the study 34 period to infer genetic and potential antigenic changes in circulating viruses and determinants 35 of clinical outcome.

36

37 **Results.** We generated and analyzed a total of 383 A(H1N1)pdm09 virus genome sequences. 38 Phylogenetic analyses revealed that multiple genetic groups (clades, subclades, and subgroups) 39 of A(H1N1)pdm09 virus circulated in Kenya over the study period; these evolved away from 40 their vaccine strain, forming clades 7 and 6, subclades 6C, 6B, and 6B.1, and subgroups 6B.1A 41 and 6B.1A1. Several amino acid substitutions among circulating viruses were associated with 42 continued evolution of the viruses, especially in antigenic epitopes and receptor binding sites 43 (RBS) of circulating viruses. Disease severity reduced with increase in age among children 44 aged <5 years.

45

46 **Conclusion.** Our study highlights the utility of genomic surveillance to monitor the 47 evolutionary changes of influenza viruses. Routine influenza surveillance with broad 48 geographic representation and whole genome sequencing capacity to inform on the severity of 49 circulating strains could improve selection of influenza strains for inclusion in vaccines.

51 **Introduction**

52 The first pandemic of the $21st$ century was a result of an influenza A virus (IAV) designated 53 A(H1N1)pdm09 virus, which emerged in North America during March-April 2009 and spread 54 rapidly among humans [1-3]. A(H1N1)pdm09 virus displaced seasonal A(H1N1) virus and has 55 continued to circulate in subsequent years alongside influenza A(H3N2) and B viruses globally 56 [4-6], causing annual seasonal epidemics [7-9]. The rapid ability of the virus to spread globally 57 upon its emergence highlights the public health threat posed by emergent viruses [3, 10, 11]. 58 The countrywide surveillance for influenza viruses among medically-attended patients in 59 Kenya since the emergence of the A(H1N1)pdm09 virus strain allows for exploring the 60 phenotypic characteristics of the virus [7, 12, 13]. 61

62 We characterized the genetic and antigenic evolution in A(H1N1)pdm09 viruses circulating in 63 Kenya between 2009 and 2018 using codon-complete gene sequences generated through next-64 generation sequencing (NGS). We then utilized genetic sequence data and available clinical 65 information to investigate determinants of clinical outcome among hospitalized children aged $66 \leq 5$ years.

67

68 **Materials and Methods**

69 **Study design.** Samples analyzed in this study were collected between June 2009 and 70 December 2018 through two health facility-based surveillance networks in Kenya as detailed 71 previously [13]. The first involved continuous countrywide surveillance for influenza through 72 severe acute respiratory illness (SARI) sentinel hospital reporting undertaken at six sites 73 supported by the Centers for Disease Control (CDC)-Kenya Country office: Kenyatta National 74 Hospital (KNH), Nakuru County and Referral Hospital (CRH), Nyeri CRH, Kakamega CRH,

75 Siaya CRH, and Coast General Teaching and Referral Hospital [7, 8, 13-16]. The second was 76 the pediatric viral pneumonia surveillance undertaken at Kilifi County Hospital (KCH) [12].

77

78 In the CDC-supported surveillance sites (CDC-Kenya), SARI was defined as acute onset of 79 illness (within the last 14 days) among hospitalized patients of all ages with cough and reported 80 fever (feverish) or a recorded temperature of $\geq 38^{\circ}$ C. Demographics, underlying diseases, and 81 signs and symptoms were collected from patients who met the case definition; the patients were 82 also assessed by study clinicians on physical and clinical findings. Furthermore, among 83 hospitalized children aged <5 years, additional clinical information including difficulty in 84 breathing, lower chest wall indrawing, inability to drink or breastfeed, and nasal flaring were 85 recorded. Chart review was done at the time of discharge or death to collect clinical outcome 86 data. In the second facility-based surveillance undertaken at KCH from January 2009 through 87 December 2018, a definition of pediatric viral pneumonia among children aged 1 day to 59 88 months presenting with syndromic severe or very severe pneumonia was used. A history of 89 cough for <30 days or difficulty breathing, when accompanied by lower chest wall indrawing 90 was defined as severe pneumonia; a history of cough for <30 days or difficulty breathing, when 91 accompanied by any one of prostration (including inability to feed or drink), coma, or 92 hypoxemia (oxygen saturation <90%) was defined as very severe pneumonia [7, 16].

93

94 We selected a total of 418 (31.9%) A(H1N1)pdm09 virus positive SARI samples for this 95 analysis based on real-time reverse-transcription (RT)-PCR cycle threshold (Ct) of <35.0 (as 96 proxy for high viral load), adequate sample volume for RNA extraction (>140 μL), and 97 balanced distribution of samples based on surveillance sites and years. We also identified a 98 total of 157 IAV positive specimens from the KCH surveillance site. These were not

99 subsequently subtyped for influenza A(H1N1)pdm09 and A(H3N2) viruses. Therefore, we 100 utilized all these specimens in the current analysis.

101

102 **RNA extraction and multi-segment real-time PCR (M-RTPCR) for IAV.** We performed 103 viral nucleic acid extraction from IAV and A(H1N1)pdm09 virus positive samples using the 104 QIAamp Viral RNA Mini Kit (Qiagen). We then reverse transcribed the extracted RNA, and 105 amplified the complete coding region of IAV genome in a single M-RTPCR using the Uni/Inf 106 primer set [17]. We evaluated successful amplification by running the products on 2% agarose 107 gel and visualized the reaction on a UV transilluminator after staining with RedSafe Nucleic 108 Acid Staining solution (iNtRON Biotechnology Inc.,).

109

110 **IAV NGS and virus genome assembly.** Following PCR, we purified the amplicons with 1X 111 AMPure XP beads (Beckman Coulter Inc., Brea, CA, USA), quantified amplicons with Quant-112 iT dsDNA High Sensitivity Assay (Invitrogen, Carlsbard, CA, USA), and normalized 113 amplicons to 0.2 ng/μL. We generated indexed paired-end libraries from 2.5 μL of 0.2 ng/μL 114 amplicon pool using Nextera XT Sample Preparation Kit (Illumina, San Diego, CA, USA) 115 following the manufacturer's protocol. We then purified amplified libraries using 0.8X 116 AMPure XP beads, quantitated libraries using Quant-iT dsDNA High Sensitivity Assay 117 (Invitrogen, Carlsbard, CA, USA), and evaluated libraries for fragment size in the Agilent 2100 118 BioAnalyzer System using the Agilent High Sensitivity DNA Kit (Agilent Technologies, Santa 119 Clara, CA, USA). We diluted the libraries to 2nM in preparation for pooling and denaturation 120 for running on the Illumina MiSeq (Illumina, San Diego, CA, USA). We then NaOH denatured 121 pooled libraries, diluted libraries to 12.5 pM, and sequenced on the Illumina MiSeq using 2 x 122 250 bp paired end reads with the MiSeq v2 500 cycle kit (Illumina, San Diego, CA, USA). We 123 added five percent Phi-X (Illumina, San Diego, CA, USA) spike-in to the libraries to increase

124 library diversity by creating a more diverse set of library clusters. We carried out contiguous 125 (contigs) nucleotide sequence assembly from the sequence data using the FLU module of the 126 Iterative Refinement Meta-Assembler (IRMA) using IRMA default settings. We deposited all 127 the generated sequence data in the Global Initiative on Sharing All Influenza Data (GISAID) 128 EpiFluTM database (https://platform.gisaid.org/epi3/cfrontend).

129

130 **Phylogenetic clustering and genetic group classification.** We aligned and translated 131 consensus nucleotide sequences for all gene segments in AliView version 1.26 132 (https://ormbunkar.se/aliview/). We then reconstructed Maximum-likelihood (ML) trees for 133 the individual gene segments using IQ-TREE version 2.0.7 (http://www.iqtree.org/). The 134 software initiates tree reconstruction after assessment and selection of the best model of 135 nucleotide substitution for alignment. We linked the ML trees to various metadata and 136 visualized using R ggtree version 2.4.2 in R programming software v4.0.2 137 (http://www.rstudio.com/). We used the codon-complete hemagglutinin (HA) sequences of all 138 viruses to characterize A(H1N1)pdm09 virus strains into genetic groups (i.e., clades, subclades, 139 and subgroups) using Phylogenetic Clustering using Linear Integer Programming (PhyCLIP) 140 v2.0 (https://github.com/alvinxhan/PhyCLIP). We downloaded vaccine strains and reference 141 viruses from GISAID EpiFluTM database (https://platform.gisaid.org/epi3/cfrontend). We 142 aligned and reconstructed ML trees using vaccine strains, reference viruses, and translated 143 Kenyan A(H1N1)pdm09 viruses.

144

145 **Genetic characterization of amino acid substitutions in surface glycoproteins, matrix, and** 146 **non-structural proteins.** We aligned the hemagglutinin (HA) and neuraminidase (NA) 147 glycoproteins, matrix (M2), and non-structural 1 (NS1) gene segments of A(H1N1)pdm09 148 virus from this study using MAFFT version 7.475 (https://mafft.cbrc.jp/alignment/software/).

149 We identified the amino acid substitutions in the antigenic epitopes (Sa, Sb, Ca₁, Ca₂ and Cb) 150 [18], receptor binding sites (RBS), and potential glycosylation sites of HA1 subunit of HA 151 protein and substitutions in the codon-complete HA, NA, M2, and NS1 protein sequences of 152 A(H1N1)pdm09 viruses using Flusurver (https://flusurver.bii.a-star.edu.sg; accessed on June 153 01, 2021). We generated highlighter plots of Kenyan and reference sequences (obtained from 154 the Global Initiative on Sharing All Influenza Data (GISAID) $EpiFlu^{TM}$ database -155 https://platform.gisaid.org/epi3/cfrontend) using inhouse python scripts to visualize amino acid 156 differences in M2 and NS1 protein sequences among the sampled viruses.

157

158 **Predictors of severe infection among hospitalized children aged <5 years.** We used 159 multivariable logistic regression in Stata version 16 (Stata Corp, College Station, Texas, USA) 160 to investigate the predictors of severe infection among hospitalized patients. Only samples 161 collected from hospitalized children aged <5 years from CDC-Kenya and KCH surveillance 162 were used to estimate the predictors of severe infection. Children hospitalized with fever and 163 acute cough were categorized as severe if they had breathing difficulty and/or lower chest wall 164 indrawing, or otherwise non-severe. The predictors investigated included patient age 165 (categorized as <12 months, 12-23 months, and ≥24 months), location of surveillance sites, 166 year of A(H1N1)pdm09 virus sampling (pandemic period, 2009-10; post pandemic period, 167 2011 onwards), A(H1N1)pdm09 virus genetic group, antigenic epitope substitutions, NS1 168 protein substitutions, and Ct values as proxy for viral load distributed in tertiles.

169

170 **Ethics.** Ethical clearance for the study was granted by the Kenya Medical Research Institute 171 (KEMRI) Scientific Steering Committee (SSC# 1899, 2558, and 2692) and KEMRI - 172 Wellcome Trust Research Programme Scientific and Ethical Review Unit (SERU# 1055, 1433, 173 and 3044). Informed consent was sought and received from the study participants for the study.

174 **Results**

186 **Table 1.** Sociodemographic and clinical characteristics of hospitalized patients in severe acute

187 respiratory illness (SARI) and viral pneumonia surveillances in Kenya, 2009-18.

188

189 **‡** Chest in-drawing, nasal flaring, unable to drink/breastfeed at all, and lethargy in patients aged <5

190 years in SARI surveillance. SARI, severe acute respiratory illness.

192 **Circulation of A(H1N1)pdm09 virus strains in Kenya and their patterns of antigenic**

193 **drift.** Phylogenetic analyses revealed that multiple genetic groups of influenza 194 A(H1N1)pdm09 virus circulated in Kenya over the study period and evolved away from their 195 vaccine strain, **Figure 1**. All Kenyan viruses from 2009-18 evolved away from the vaccine 196 strains A/California/07/2009 (H1N1pdm09)-like virus and A/Michigan/45/2015 197 (H1N1pdm09)-like virus. The A(H1N1)pdm09 virus strains from 2009 to 2016 (n=324; 198 84.6%) evolved away from the 2009-17 Northern Hemisphere (NH) and 2009-16 Southern 199 Hemisphere (SH) vaccine strain A/California/07/2009 (H1N1pdm09)-like virus and fell into 200 clade 7 (n=97, 25.3%), clade 6 (n=132, 34.5%), subclade 6C (n=10, 2.6%), subclade 6B (n=47, 201 12.3%), and subclade 6B.1 (n=38, 9.9%), respectively. All the viruses from 2018 evolved away 202 from the 2017-18 NH and 2017 SH vaccine strain A/Michigan/45/2015 (H1N1pdm09)-like 203 virus and fell into subgroup 6B.1A (n=57, 14.9%) and subgroup 6B.1A1 (n=2, 0.5%), 204 respectively.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.13.22273796;](https://doi.org/10.1101/2022.04.13.22273796) this version posted April 13, 2022. The copyright holder for this preprint

Figure 1. Maximum-likelihood phylogenetic tree of A(H1N1)pdm09 virus sequences from Kenya collected between 2009 and 2018, A(H1N1)pdm09 virus vaccine strains, and reference viruses. This is a time-calibrated phylogenetic tree with time shown on the x-axis. Branches are colored based on Kenyan, vaccine, and reference strains as shown in the color key. Amino acid substitutions in HA1 and HA2 subunits, which define A(H1N1)pdm09 virus genetic groups are also shown (HA2 substitutions are labelled in purple as shown in the color key).

221

222 Comparison of the deduced amino acid sequences of the viruses identified in hospitalized 223 patients relative to the vaccine strains from which all the 2009-18 strains considerably evolved 224 revealed significant amino acid substitutions in antigenic epitopes and RBS among the 225 circulating A(H1N1)pdm09 virus strains (**Table 2**). There were 13 amino acid substitutions 226 across the five antigenic sites among sampled Kenyan viruses. Ranking from the most variable 227 site, Sa, Ca_{2,} Sb, Ca₁, and Cb had two, six, six, three, and one substitution, respectively. The 228 most frequent HA substitution per site for Sa, Sb, Ca₁, Ca₂ and Cb was K163Q, S185T, S203T, 229 A141E, and S74R, respectively. HA substitutions S203T and S185T were the most dominant 230 substitutions occurring in 100% and 59.3% (227/383) viruses from 2009-18, respectively. In 231 addition, we observed previously described HA substitutions at the RBS (A186T and D222E) 232 and glycosylation sites (A186T and N125S) of the viruses.

236

237 NH, Northern Hemisphere; SH, Southern Hemisphere.

238 **†** A (H1N1)pdm09 antigenic sites are represented as Sa-**a**; Sb-**b**; Ca1-**c**;, Ca2-**d**; and Cb-**e**.

239 **‡** Recommended vaccines for each influenza season are adopted from Global Initiative on Sharing All

240 Influenza Data (GISAID) (https://www.gisaid.org/resources/human-influenza-vaccine-composition/).

242

241

```
243 Genetic and antigenic characterization of NA, M2, and NS1 proteins. All NA proteins 
244 lacked the H275Y marker associated with resistance to neuraminidase inhibitors. However, 
245 seven (1.8%) NA proteins had substitutions T362I (3), I117M (3), and V234I (1). Additionally, 
246 all the Kenyan viruses contained the adamantine-resistance marker S31N, Figure 2. All 59 
247 viruses from 2018 had six amino acid substitutions (E55K, L90I, I123V, E125D, K131E, and 
248 N205S) in NS1 protein, Figure 3.
```


253

254 **Figure 2.** Highlighter plot of M2 protein sequences of A(H1N1)pdm09 viruses from Kenya 255 showing the adamantine-resistance marker S31N amino acid substitution in M2 protein. The 256 substitution was observed in all the A(H1N1)pdm09 viruses collected in Kenya between 2009 257 and 2018. Sequences were aligned with A/Brisbane/59/2007.

258

263

264 **Figure 3.** Highlighter plot of NS1 protein sequences of A(H1N1)pdm09 viruses from Kenya 265 showing the NS1 protein substitutions: E55K, L90I, I123V, E125D, K131E, and N205S. The 266 sequences were aligned with vaccine strain A/California/07/2009. The substitutions were 267 reported for 59 virus sequences collected from hospitalized patients in 2018 from CDC-268 supported surveillance and KCH pediatric viral pneumonia surveillance. CDC, Centers for 269 Disease Control; KCH, Kilifi County Hospital.

271 **Predictors of severe infection among hospitalized children aged <5 years.** We observed

- 272 that severity of infection reduced with increase in age. Children aged \geq 24 months were less
- 273 likely to have severe infection compared to children aged 0-11 months (adjusted odds ratio
- 274 (aOR), 0.25; 95% CI, 0.11-0.54) and that A(H1N1)pdm09 viruses of subclade 6B and clade 7
- 275 were less likely associated with severe infection compared to clade 6 viruses (aOR, 0.25; 95%)
- 276 CI, 0.09-0.72) and (aOR, 0.34; 95% CI, 0.15-0.79), respectively (**Table 3**). Ct value, year of
- 277 sampling, location of sampling, antigenic epitope substitutions, and NS1 protein substitutions
- 278 were not associated with severe infection.

280 **Table 3.** Predictors of severe infection among hospitalized children aged <5 years.

281

282

283 aOR, adjusted odds ratio; CI, confidence interval; Ct; cycle threshold.

284 **Discussion**

285 We observed that A(H1N1)pdm09 viruses circulating in Kenya from 2009-18 evolved away 286 from their vaccine strain over the study period. Kenyan virus strains from 2009-16 evolved 287 away from the 2009-17 NH and 2009-16 SH vaccine strain A/California/07/2009 288 (H1N1pdm09)-like virus and fell into clades 7 and 6, and subclades 6C, 6B, and 6B.1, 289 respectively. All viruses from 2018 evolved away from the 2017-18 NH and 2017 SH vaccine 290 strain A/Michigan/45/2015 (H1N1pdm09)-like virus and fell into subgroups 6B.1A and 291 6B.1A1, respectively. We identified considerable amino acid substitutions in antigenic 292 epitopes and RBS among the circulating viruses, which confirms the continued evolution of 293 circulating influenza viruses in Kenya. We recently reported that the evolutionary dynamics of 294 A(H1N1)pdm09 virus in Kenya was associated with multiple virus introductions into the 295 country between 2009 and 2018, although only a few of those introductions instigated local 296 seasonal epidemics that then established local transmission clusters across the country [13]. 297 We also observed substitutions in NA protein, which have been associated with reduced 298 susceptibility to neuraminidase inhibitors in vitro [19], substitutions in M2 protein associated 299 with adamantine-resistance, and substitutions in NS1 protein that possibly result in increased 300 virulence [20]. Nonetheless, we were not able to associate viral genetic changes and 301 substitutions with increased severity.

302

303 Analysis of virus sequence data from Kenya during the pandemic in 2009 identified the 304 introduction of clades 2 and 7 viruses into Kenya [21]. We recently confirmed these findings 305 and showed that clades 6 and 7 viruses were introduced into Kenya, disseminated countrywide, 306 and persisted across multiple epidemics as local transmission clusters [13]. A recent study from 307 Kenya reported the circulation of clade 6B, subclade 6B.1, and subclade 6B.2 viruses in the 308 2015-18 influenza seasons [22]. Here, through detailed genomic analysis, we extend these

309 observations and show that multiple influenza strains were introduced into Kenya and spread 310 countrywide over the study period. Most of the amino acid substitutions associated with the 311 continued evolution of A(H1N1)pdm09 viruses in Kenya have also been reported in other 312 studies in Africa [22-25] and Asia [26, 27]. Therefore, the continuing evolution of 313 A(H1N1)pdm09 viruses in Kenya is in part due to the global circulation of influenza viruses.

314

315 The genetic diversity of A(H1N1)pdm09 viruses in specific regions arising from multiple virus 316 introductions and subsequent establishment of local transmission clusters [13] composed of 317 viruses harboring considerable amino acid substitutions in antigenic epitopes and RBS could 318 lead to predominance of circulating viruses that are not closely matched to previously selected 319 vaccine strains as shown in our study. In countries like Kenya, where influenza virus spread is 320 year-round [9], there also exists unpredictability of which genetic virus strain may predominate 321 and when. Influenza vaccines with broad coverage ("universal" vaccines) could be key to 322 managing the influenza disease burden in such settings. Currently, Kenya does not have a 323 national influenza vaccination policy [28], but it would be important to consider deployment 324 of quadrivalent influenza vaccines with representative A(H1N1)pdm09 virus, A(H3N2) virus, 325 and both influenza B virus lineages (B/Victoria and B/Yamagata) for optimal vaccine 326 effectiveness [13, 29, 30]. It will also be important to investigate further whether the use of SH 327 or NH formulated vaccines could have a place in tropical regions like in Kenya, where virus 328 importations from both hemispheres are common.

329

330 Specific influenza virus gene segment phylogenies and genetic group memberships have been 331 associated with disease severity [31]. Although we did not observe associations between 332 genetic group membership or substitutions with disease severity, these findings underscore the 333 importance of reporting genetic surveillance data along with epidemiological data to allow for

334 analysis of factors that may increase risk of influenza and impact disease severity [32]. 335 Although we did not observe association between viral load and disease severity, larger studies 336 have reported this association among hospitalized patients with pneumonia infection [33], 337 which underscores the need for multi-site studies with improved statistical power to estimate 338 associations. We reported a reduction in disease severity with increase in age in children aged 339 <5 years, which corroborates the evidence that children aged <6 months may experience more 340 severe influenza related complications [34].

341

342 The study had some limitations. First, the analysis in this report only involved the HA, NA, 343 M2, and NS1 gene segments of A(H1N1)pdm09 virus. Although these regions are important 344 in understanding antigenic drift and antiviral drug resistance in influenza viruses, important 345 changes in other gene segments, for example, mutations associated with increased 346 pathogenicity may not have been captured. Secondly, the prioritized samples were selected 347 based on anticipated probability of successful sequencing inferred from the sample's viral load 348 as indicated by the diagnosis Ct value. Such a strategy ultimately avoided NGS of some 349 samples that may have been critical in inferring additional genetic characteristics of circulating 350 influenza viruses. Lastly, the analysis in this report did not include phenotypic analyses to 351 assess the effect of observed substitutions on virulence, pathogenicity, and transmissibility of 352 influenza viruses.

353

354 In conclusion, our study highlights the utility of genomic surveillance to monitor the 355 evolutionary changes of influenza viruses within a country and the utility of combined genetic 356 and epidemiological data to improve understanding of influenza season severity and guide 357 intervention. Routine influenza surveillance with broad geographic representation and whole

- 358 genome sequencing capacity to inform on the severity of circulating strains could improve
- 359 selection of influenza strains for inclusion in vaccines.

361 **Supporting information**

362 **Conflict of interest.** None

363

364 **Disclosure.** The findings and conclusions in this report are those of the authors and do not

365 necessarily represent the official position of the Centers for Disease Control and Prevention.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.04.13.22273796;](https://doi.org/10.1101/2022.04.13.22273796) this version posted April 13, 2022. The copyright holder for this preprint

376 **References**

377 1. Garten, R.J., et al., *Antigenic and genetic characteristics of swine-origin 2009 A(H1N1)* 378 *influenza viruses circulating in humans.* Science, 2009. **325**(5937): p. 197-201. 379 2. Dawood, F.S., et al., *Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in* 380 *Humans.* New England Journal of Medicine, 2009. **360**(25): p. 2605-2615. 381 3. Smith, G.J., et al., *Origins and evolutionary genomics of the 2009 swine-origin H1N1* 382 *influenza A epidemic.* Nature, 2009. **459**(7250): p. 1122-5. 383 4. Baillie, G.J., et al., *Evolutionary dynamics of local pandemic H1N1/2009 influenza* 384 *virus lineages revealed by whole-genome analysis.* J Virol, 2012. **86**(1): p. 11-8. 385 5. Zehender, G., et al., *Reconstruction of the evolutionary dynamics of the A(H1N1)pdm09* 386 *influenza virus in Italy during the pandemic and post-pandemic phases.* PLoS One, 387 2012. **7**(11): p. e47517. 388 6. Venter, M., et al., *Evolutionary dynamics of 2009 pandemic influenza A virus subtype* 389 *H1N1 in South Africa during 2009-2010.* J Infect Dis, 2012. **206 Suppl 1**: p. S166-72. 390 7. Katz, M.A., et al., *Results From the First Six Years of National Sentinel Surveillance* 391 *for Influenza in Kenya, July 2007–June 2013.* PLoS ONE, 2014. **9**(6): p. e98615. 392 8. Emukule, G.O., et al., *The burden of influenza and RSV among inpatients and* 393 *outpatients in rural western Kenya, 2009-2012.* PLoS One, 2014. **9**(8): p. e105543. 394 9. Emukule, G.O., et al., *Influenza activity in Kenya, 2007-2013: timing, association with* 395 *climatic factors, and implications for vaccination campaigns.* Influenza and Other 396 Respiratory Viruses, 2016. **10**(5): p. 375-385. 397 10. Lemey, P., M. Suchard, and A. Rambaut, *Reconstructing the initial global spread of a* 398 *human influenza pandemic: a Bayesian spatial-temporal model for the global spread* 399 *of H1N1pdm.* PLoS Curr Biol, 2009. **1**(RRN1031). 400 11. Rambaut, A. and E. Holmes, *The early molecular epidemiology of the swine-origin* 401 *A/H1N1 human influenza pandemic.* PLoS Currents, 2009. **1**: p. RRN1003. 402 12. Nokes, D.J., et al., *Incidence and severity of respiratory syncytial virus pneumonia in* 403 *rural Kenyan children identified through hospital surveillance.* Clin Infect Dis, 2009. 404 **49**(9): p. 1341-9. 405 13. Owuor, D.C., et al., *Characterizing the Countrywide Epidemic Spread of Influenza* 406 *A(H1N1)pdm09 Virus in Kenya between 2009 and 2018.* Viruses, 2021. **13**(10): p. 407 1956. 408 14. Katz, M.A., et al., *Epidemiology, Seasonality, and Burden of Influenza and Influenza-*409 *Like Illness in Urban and Rural Kenya, 2007-2013;2010.* The Journal of Infectious 410 Diseases, 2012. **206**: p. S53-S60. 411 15. Feikin, D.R., et al., *The burden of common infectious disease syndromes at the clinic* 412 *and household level from population-based surveillance in rural and urban Kenya.* 413 PLoS One, 2011. **6**(1): p. e16085. 414 16. Emukule, G.O., et al., *The Epidemiology and Burden of Influenza B/Victoria and* 415 *B/Yamagata Lineages in Kenya, 2012-2016.* Open forum infectious diseases, 2019. 416 **6**(10): p. ofz421-ofz421. 417 17. Zhou, B. and D.E. Wentworth, *Influenza A virus molecular virology techniques.* 418 Methods Mol Biol, 2012. **865**: p. 175-92. 419 18. A.J., C., et al., *The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin* 420 *(H1 subtype).* Cell, 1982. **31**(2 Pt 1): p. 417-427. 421 19. Nguyen, H.T., A.M. Fry, and L.V. Gubareva, *Neuraminidase inhibitor resistance in* 422 *influenza viruses and laboratory testing methods.* Antivir Ther, 2012. **17**(1 Pt B): p. 423 159-73.

